In the MAIC analysis of patients with CP-CML without baseline response, ponatinib showed a nonsignificantly higher MMR and significantly higher BCR::ABL1IS ≤1% by 12 months compared with asciminib. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.